Biosimilar market will reach $3.7bn in 2015
News Mar 22, 2011
Mark Hollis, healthcare analyst at Datamonitor, comments: “With the market shares of first-generation biologic drugs stagnating or declining, biosimilar monoclonal antibodies (MAbs) and second-generation biosimilars represent a high-value proposition for biosimilar manufacturers and key drivers for future growth”.
“However, despite the introduction of biosimilar approval pathways in the US, EU and Japan, the growing use of biologics and the need for more cost-effective treatments, there remain a large number of barriers to achieving commercial success in developed markets.”
Nevertheless, although existing biosimilar players have the advantage of an established reputation and relationships with key stakeholders, branded pharma companies are increasingly looking to biosimilars as one route to drive sales going forward, using partnership and M&A deals to achieve their goals.
Consequently, Datamonitor argues that the future biosimilars market in the US, EU and Japan will continue to remain dominated by the existing biosimilars players, with the addition of select branded pharma companies. Furthermore, emerging market biosimilar players are now looking to expand into global markets too, through partnerships with international pharma companies.
For more information on these findings, please click here for a comparative analysis of biosimilar drivers and resistors, key players, market access, pricing, and future launches across multiple markets including: the US, Japan, France, Germany, Italy, Spain, the UK, Australia, Brazil, Russia, India and China.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE